Azabicyclic compounds, process for their preparation and pharmaceutical compositions containing them
申请人:BEECHAM GROUP PLC
公开号:EP0289170A2
公开(公告)日:1988-11-02
Compounds of formula (I), or a pharmaceutically acceptable salt thereof:
Y-CO-L-Z (I)
wherein
L is NH or O;
Y is a group of formula (a), (b) or (c):
wherein
R₁ and R₂, R₅ and R₆, R₉ and R₁₀, are independently selected from hydrogen or halogen;
X is N or CR₃
wherein
R₃ is hydrogen or C₁₋₆ alkoxy;
R₄ is hydrogen, halogen, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ alkylsulphonyl, C₁₋₆ alkylsulphinyl, C₁₋₇ acyl, cyano, C₁₋₆ alkoxycarbonyl, C₁₋₇ acylamino, hydroxy, nitro or amino, aminocarbonyl, or aminosulphonyl, optionally N-substituted by one or two groups selected from C₁₋₆ alkyl, C₃₋₈ cycloalkyl, and C₃₋₈ cycloalkyl C₁₋₄ alkyl or disubstituted by C₄ or C₅ polymethylene; phenyl or phenyl C₁₋₄ alkyl group optionally substituted in the phenyl ring by one or two of halogen, C₁₋₆ alkoxy or C₁₋₆ alkyl groups;
one of R₇ and R₈ is C₁₋₆ alkyl and the other is C₁₋₆ alkyl, phenyl or phenyl C₁₋₄ alkyl optionally substituted in either phenyl ring by one or two of C₁₋₆ alkyl, C₁₋₆ alkoxy or halogen; or
R₇ and R₈ together are C₂₋₆ polymethylene or C₂₋₅ polymethylene interrupted by an -O- linkage;
R₁₁ is hydrogen or C₁₋₆ alkoxy;
R₁₂ is hydrogen, halogen, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ alkylsulphonyl, C₁₋₆ alkylsulphinyl, C₁₋₇ acyl, cyano, C₁₋₆ alkoxycarbonyl, C₁₋₇ acylamino, hydroxy, nitro or amino, aminocarbonyl, or aminosulphonyl, optionally N-substituted by one or two groups selected from C₁₋₆ alkyl, C₃₋₈ cycloalkyl, and C₃₋₈ cycloalkyl C₁₋₄ alkyl or disubstituted by C₄ or C₅ polymethylene; phenyl or phenyl C₁₋₄ alkyl optionally substituted in either phenyl ring by one or two of halogen, C₁₋₆ alkoxy or C₁₋₆ alkyl groups;
Z is a group of formula (d), (e) or (f):
wherein
n is 2 or 3;
p is 1 or 2;
q is 1 to 3;
r is 1 to 3; and
R₁₃ or R₁₄ is C₁₋₄ alkyl;
having 5-HT₃ receptor antagonist activity, a process for their preparation and their use as pharmaceuticals.
式 (I) 化合物或其药学上可接受的盐:
Y-CO-L-Z (I)
其中
L 是 NH 或 O
Y 是式 (a)、(b) 或 (c) 的基团:
其中
R₁ 和 R₂、R₅ 和 R₆、R₉ 和 R₁₀ 独立选自氢或卤素;
X 是 N 或 CR₃
其中
R₃ 是氢或 C₁₋₆ 烷氧基;
R₄是氢、卤素、CF₃、C₁₋₆ 烷基、C₁₋₆ 烷氧基、C₁₋₆ 烷硫基、C₁₋₆ 烷基磺酰基、C₁₋₆ 烷基亚磺酰基、C₁₋₇酰基、氰基、C₁₋₆ 烷氧基羰基、C₁₋₇酰氨基、羟基、硝基或氨基、氨基甲酸乙酯、氨基甲酸乙酯、氨基甲酸乙酯、氨基甲酸乙酯、氨基甲酸乙酯、氨基甲酸乙酯、氨基甲酸乙酯、氨基甲酸乙酯、氨基甲酸乙酯硝基或氨基、氨基羰基或氨基磺酰基,可选择由一个或两个选自 C₁₋₆烷基的基团 N 取代、C₃₋₈ 环烷基和 C₃₋₈ 环烷基 C₁₋₄烷基或被 C₄ 或 C₅ 聚亚甲基二取代;苯基或苯基 C₁₋₄烷基,可选择在苯基环上被一个或两个卤素、C₁₋₆烷氧基或 C₁₋₆烷基取代;
R₇ 和 R₈ 中的一个是 C₁₋₆ 烷基,另一个是 C₁₋₆ 烷基、苯基或 C₁₋₄烷基,可选择在任一苯基环上被一个或两个 C₁₋₆ 烷基、C₁₋₆ 烷氧基或卤素取代;或
R₇ 和 R₈ 合在一起是 C₂₋₆ 聚亚甲基或被 -O- 连接中断的 C₂₋₅ 聚亚甲基;
R₁₁ 是氢或 C₁₋₆ 烷氧基;
R₁₂是氢、卤素、CF₃、C₁₋₆ 烷基、C₁₋₆ 烷氧基、C₁₋₆ 烷硫基、C₁₋₆ 烷基磺酰基、C₁₋₆ 烷基亚磺酰基、C₁₋₇酰基、氰基、C₁₋₆ 烷氧羰基、C₁₋₇酰氨基、羟基、硝基或氨基、氨基甲酸乙酯、氨基甲酸乙酯、氨基甲酸乙酯、氨基甲酸乙酯、硝基或氨基、氨基羰基或氨基磺酰基,可选择由一个或两个选自 C₁₋₆烷基的基团 N 取代、C₃₋₈ 环烷基和 C₃₋₈ 环烷基 C₁₋₄烷基或被 C₄ 或 C₅ 聚亚甲基二取代;苯基或苯基 C₁₋₄烷基,可任选在任一苯基环上被一个或两个卤素、C₁₋₆烷氧基或 C₁₋₆烷基取代;
Z 是式(d)、(e)或(f)的基团:
其中
n 是 2 或 3
p 是 1 或 2
q 是 1 至 3
r 为 1 至 3;以及
R₁₃ 或 R₁₄ 是 C₁₋₄ 烷基;
具有 5-HT₃ 受体拮抗剂活性,其制备方法及其作为药物的用途。